V

ViroGates A/S
CSE:VIRO

Watchlist Manager
ViroGates A/S
CSE:VIRO
Watchlist
Price: 14.2 DKK -3.73% Market Closed
Market Cap: 109.9m DKK

ViroGates A/S
Net Issuance of Common Stock

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

ViroGates A/S
Net Issuance of Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
V
ViroGates A/S
CSE:VIRO
Net Issuance of Common Stock
kr8.1m
CAGR 3-Years
-4%
CAGR 5-Years
1%
CAGR 10-Years
N/A
GN Store Nord A/S
CSE:GN
Net Issuance of Common Stock
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Ambu A/S
CSE:AMBU B
Net Issuance of Common Stock
kr11m
CAGR 3-Years
-5%
CAGR 5-Years
-30%
CAGR 10-Years
N/A
Demant A/S
CSE:DEMANT
Net Issuance of Common Stock
-kr1.7B
CAGR 3-Years
13%
CAGR 5-Years
-15%
CAGR 10-Years
-8%
No Stocks Found

ViroGates A/S
Glance View

Market Cap
109.8m DKK
Industry
Health Care

ViroGates A/S develops and markets prognostic products for the healthcare sector. Its develops a product line suPARnostic, which measures the amount of amount of soluble urokinase Plasminogen Activator Receptor protein (suPAR) in human blood. The plasma level of suPAR reflects immune activation and is increased in such infectious diseases as HIV-1-infection, malaria, tuberculosis, Streptococcus pneumonia bacteraemia, sepsis, pneumococcal pneumonia and bacterial and viral CNS infection. Also, high suPAR levels are associated with increased inflammation, disease progression and risk of mortality. Thus, measuring suPAR levels serves as a marker to determine chances for survival upon hospital admission, as well as for monitoring for prevention of disease progression and earlier intervention time point. suPARnostic has two versions: Quantitative Point of Care Quick Triage test, which serves for patient triage in acute care, and Quantitative ELISA Assay that aims at clinical routine use.

VIRO Intrinsic Value
1.92 DKK
Overvaluation 86%
Intrinsic Value
Price
V

See Also

What is ViroGates A/S's Net Issuance of Common Stock?
Net Issuance of Common Stock
8.1m DKK

Based on the financial report for Sep 30, 2025, ViroGates A/S's Net Issuance of Common Stock amounts to 8.1m DKK.

What is ViroGates A/S's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 5Y
1%

Over the last year, the Net Issuance of Common Stock growth was -38%. The average annual Net Issuance of Common Stock growth rates for ViroGates A/S have been -4% over the past three years , 1% over the past five years .

Back to Top